Comparison Chart Protagonist Therapeutics, Inc.
Stocks
PTGX
US74366E1029
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
00:00:00 31/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 144.85 USD | +0.35% |
|
+4.64% | +65.85% |
| 10-23 | UK approves J&J's oral psoriasis pill | RE |
| 10-12 | UBS Initiates Coverage on Protagonist Therapeutics With Buy Rating, $184 Price Target | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PROTAGONIST THERAPEUTICS, INC. | Other Biotechnology & Medical Research | +0.35% | +4.64% | +65.85% | +84.24% | +364.86% | 9.37B |  |  | |
- Stock Market
- Stocks
- PTGX Stock
- Charts Protagonist Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
